keyword
MENU ▼
Read by QxMD icon Read
search

primary progressive multiple sclerosis

keyword
https://www.readbyqxmd.com/read/27919489/cognitive-event-related-potentials-in-multiple-sclerosis-correlation-with-mri-and-neuropsychological-findings
#1
Vasilios K Kimiskidis, Vasileios Papaliagkas, Kyriaki Sotirakoglou, Zoi K Kouvatsou, Victoria K Kapina, Efrosini Papadaki, Vaia Tsimourtou, Elvira Masoura, Dimitrios A Kazis, Sotirios Papayiannopoulos, Triantafyllos Geroukis, Sevasti Bostanjopoulou
BACKGROUND: Cognitive event-related potentials (ERPs) have been previously correlated with T2 lesion load (Τ2LL) in patients with multiple sclerosis (MS). It is currently unknown, however, whether ERPs also correlate with brain atrophy or the presence of T1 hypointense lesions ("black holes") which reflect tissue destruction and axonal loss. The primary aim of the current study is to explore the effect of neuroradiological parameters such as brain atrophy, T1 and T2 lesion load on auditory ERPs in MS patients...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919195/efficacy-and-safety-of-mitoxantrone-use-in-primary-and-secondary-progressive-multiple-sclerosis-study-site-experience-based-on-the-therapy-of-104-patients
#2
Anetta Lasek-Bal, Karina Bartoszek, Arkadiusz Steposz, Przemyslaw Puz, Wieslaw Bal, Zofia Kazibutowska
Mitoxantrone (MX) is used in patients with primary and secondary progressive as well as relapsing-remitting type of multiple sclerosis (PPMS, SPMS, RRMS). The objective of our project was to evaluate the efficacy and safety of mitoxantrone use in patients with PPMS and SPMS. Methods The retrospective study included 104 patients (mean age 54.2 ± 9.0), with PPMS (13.46%) and SPMS (86.54%) treated with mitoxantrone. During single cycle of the MX therapy a dose of 12 mg/m2 of body surface area was administred and next cycles every three months up to a total dose of 140 mg/m2 were realized...
December 6, 2016: International Journal of Neuroscience
https://www.readbyqxmd.com/read/27882837/determining-multiple-sclerosis-phenotype-from-electronic-medical-records
#3
Richard E Nelson, Jorie Butler, Joanne LaFleur, Kristin Knippenberg, Aaron W C Kamauu, Scott L DuVall
BACKGROUND: Multiple sclerosis (MS), a central nervous system disease in which nerve signals are disrupted by scarring and demyelination, is classified into phenotypes depending on the patterns of cognitive or physical impairment progression: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), or progressive-relapsing MS (PRMS). The phenotype is important in managing the disease and determining appropriate treatment. The ICD-9-CM code 340.0 is uninformative about MS phenotype, which increases the difficulty of studying the effects of phenotype on disease...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27880972/interferons-beta-versus-glatiramer-acetate-for-relapsing-remitting-multiple-sclerosis
#4
REVIEW
Loredana La Mantia, Carlo Di Pietrantonj, Marco Rovaris, Giulio Rigon, Serena Frau, Francesco Berardo, Anna Gandini, Anna Longobardi, Bianca Weinstock-Guttman, Alberto Vaona
BACKGROUND: Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile, as well as the impact on quality of life. As MS cohorts enrolled in different studies can vary significantly, head-to-head trials are considered the best approach for gaining objective reliable data when two different drugs are compared...
November 24, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27865736/ips-derived-neural-progenitor-cells-from-ppms-patients-reveal-defect-in-myelin-injury-response
#5
Alexandra M Nicaise, Erin Banda, Rosa M Guzzo, Kristen Russomanno, Wanda Castro-Borrero, Cory M Willis, Kasey M Johnson, Albert C Lo, Stephen J Crocker
Primary progressive multiple sclerosis (PPMS) is a chronic demyelinating disease of the central nervous system (CNS) currently lacking any effective treatment. Promoting endogenous brain repair offers a potential strategy to halt and possibly restore neurologic function in PPMS. To understand how the microenvironment within white matter lesions plays a role in repair we have focused on neural progenitor cells (NPCs) since these are found in lesions in PPMS and have been found to influence oligodendrocyte progenitor cell maturation (OPCs)...
November 16, 2016: Experimental Neurology
https://www.readbyqxmd.com/read/27865707/a-comprehensive-database-of-published-tdcs-clinical-trials-2005-2016
#6
REVIEW
Jean-Pascal Lefaucheur
Transcranial direct current stimulation (tDCS) is a technique of noninvasive cortical stimulation allowing significant modification of brain functions. Clinical application of this technique was reported for the first time in March 2005. This paper presents a detailed list of the 340 articles (excluding single case reports) which have assessed the clinical effect of tDCS in patients, at least when delivered to cortical targets. The reviewed conditions were: pain syndromes, Parkinson's disease, dystonia, cerebral palsy, post-stroke limb motor impairment, post-stroke neglect, post-stroke dysphagia, post-stroke aphasia, primary progressive aphasia, multiple sclerosis, epilepsy, consciousness disorders, Alzheimer's disease and other types of dementia, tinnitus, depression, auditory hallucinations and negative symptoms of schizophrenia, addiction and craving, autism, and attention disorders...
December 2016: Neurophysiologie Clinique, Clinical Neurophysiology
https://www.readbyqxmd.com/read/27826747/serum-compounds-of-energy-metabolism-impairment-are-related-to-disability-disease-course-and-neuroimaging-in-multiple-sclerosis
#7
Giacomo Lazzarino, Angela M Amorini, Axel Petzold, Claudio Gasperini, Serena Ruggieri, Maria Esmeralda Quartuccio, Giuseppe Lazzarino, Enrico Di Stasio, Barbara Tavazzi
Multiple sclerosis (MS) is characterized by primary inflammation, demyelination, and progressive neurodegeneration. A biochemical MS feature is neuronal mitochondrial dysfunction, compensated by anaerobic metabolism increase, likely aggravating progression of neurodegeneration. Here, we characterized a pragmatic serum profile of compounds related to mitochondrial energy metabolism of potential clinical use. Blood samples of 518 well characterized (disability, disease course) MS patients and 167 healthy controls were analyzed for serum purines, pyrimidines, creatinine, and lactate...
November 8, 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/27826224/graph-theory-based-brain-connectivity-for-automatic-classification-of-multiple-sclerosis-clinical-courses
#8
Gabriel Kocevar, Claudio Stamile, Salem Hannoun, François Cotton, Sandra Vukusic, Françoise Durand-Dubief, Dominique Sappey-Marinier
Purpose: In this work, we introduce a method to classify Multiple Sclerosis (MS) patients into four clinical profiles using structural connectivity information. For the first time, we try to solve this question in a fully automated way using a computer-based method. The main goal is to show how the combination of graph-derived metrics with machine learning techniques constitutes a powerful tool for a better characterization and classification of MS clinical profiles. Materials and Methods: Sixty-four MS patients [12 Clinical Isolated Syndrome (CIS), 24 Relapsing Remitting (RR), 24 Secondary Progressive (SP), and 17 Primary Progressive (PP)] along with 26 healthy controls (HC) underwent MR examination...
2016: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/27813441/primary-progressive-multiple-sclerosis-current-therapeutic-strategies-and-future-perspectives
#9
Alberto Gajofatto, Marco Turatti, Maria Donata Benedetti
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system with heterogeneous features. Primary progressive (PP) MS is a rare disease subtype characterized by continuous disability worsening from onset. No disease-modifying therapy is currently approved for PP MS due to the negative or inconsistent results of clinical trials conducted on a wide range of interventions, which are reviewed in the present paper. Areas covered: The features and results of randomized trials of disease-modifying treatments for PP MS are discussed, including immunosuppressants, immunomodulators, monoclonal antibodies, and putative neuroprotective agents...
November 4, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27803637/exercise-training-in-progressive-multiple-sclerosis-a-comparison-of-recumbent-stepping-and-body-weight-supported-treadmill-training
#10
Lara A Pilutti, John E Paulseth, Carin Dove, Shucui Jiang, Michel P Rathbone, Audrey L Hicks
Background: There is evidence of the benefits of exercise training in multiple sclerosis (MS); however, few studies have been conducted in individuals with progressive MS and severe mobility impairment. A potential exercise rehabilitation approach is total-body recumbent stepper training (TBRST). We evaluated the safety and participant-reported experience of TBRST in people with progressive MS and compared the efficacy of TBRST with that of body weight-supported treadmill training (BWSTT) on outcomes of function, fatigue, and health-related quality of life (HRQOL)...
September 2016: International Journal of MS Care
https://www.readbyqxmd.com/read/27801405/-the-application-of-high-frequency-and-itbs-transcranial-magnetic-stimulation-for-the-treatment-of-spasticity-in-the-patients-presenting-with-secondary-progressive-multiple-sclerosis
#11
Yu E Korzhova, A V Chervyakov, A G Poidasheva, I A Kochergin, A V Peresedova, M N Zakharova, N A Suponeva, L A Chernikova, M A Piradov
: Spasticity is considered to be a common manifestation of multiple sclerosis. Muscle relaxants are not sufficiently effective; more than that, some of them often cause a variety of adverse reactions. Transcranial magnetic stimulation (TMS) can be a promising new tool for the treatment of spasticity. The objective of the present study was to compare the effectiveness of the two TMS protocols: rhythmic (high-frequency) TMS (rTMS) and stimulation with the theta bursts (iTBS) in terms of their ability to reduce spasticity in the patients presenting with multiple sclerosis...
2016: Voprosy Kurortologii, Fizioterapii, i Lechebnoĭ Fizicheskoĭ Kultury
https://www.readbyqxmd.com/read/27800024/an-update-on-the-evidence-base-for-peginterferon-%C3%AE-1a-in-the-treatment-of-relapsing-remitting-multiple-sclerosis
#12
REVIEW
Pavan Bhargava, Scott D Newsome
Peginterferon β1a is a modified form of interferon β1a with a polyethylene glycol (PEG) group attached to the α-amino group of the N terminus of the interferon molecule. This modification alters the pharmacokinetic and pharmacodynamic properties of interferon β1a, enabling reduced frequency of dosing and may also result in reduced immunogenicity of the interferon β1a molecule. The efficacy of peginterferon β1a 125 µg administered subcutaneously every 2 or 4 weeks was demonstrated at the end of the placebo-controlled period in the phase III ADVANCE study; both dosing regimens met their primary endpoint of reducing annualized relapse rate (ARR) compared with placebo...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27795849/whole-genome-dna-methylation-analysis-of-peripheral-blood-mononuclear-cells-in-multiple-sclerosis-patients-with-different-disease-courses
#13
O G Kulakova, M R Kabilov, L V Danilova, E V Popova, O A Baturina, E Y Tsareva, N M Baulina, I S Kiselev, A N Boyko, A V Favorov, O O Favorova, V V Vlassov
Multiple sclerosis (MS) is a severe neurodegenerative disease of polygenic etiology affecting the central nervous system. In addition to genetic factors, epigenetic mechanisms, primarily DNA methylation, which regulate gene expression, play an important role in MS development and progression. In this study, we have performed the first whole-genome DNA methylation profiling of peripheral blood mononuclear cells in relapsing-remitting MS (RRMS) and primary-progressive MS (PPMS) patients and compared them to those of healthy individuals in order to identify the differentially methylated CpG-sites (DMSs) associated with these common clinical disease courses...
July 2016: Acta Naturae
https://www.readbyqxmd.com/read/27785735/real-world-outcomes-in-fingolimod-treated-patients-with-multiple-sclerosis-in-the-czech-republic-results-from-the-12-month-golems-study
#14
Veronika Tichá, Roman Kodým, Zuzana Počíková, Pavla Kadlecová
BACKGROUND AND OBJECTIVE: Once-daily oral fingolimod is approved in the EU as escalation treatment for adult patients with highly active relapsing multiple sclerosis (MS). The efficacy and safety profiles of fingolimod have been well established in a large clinical development programme and several papers reflecting the experience with fingolimod in real-world settings have been published to date. The GOLEMS study was designed to evaluate the efficacy, safety and tolerability of fingolimod and the impact of fingolimod treatment on disability progression and work capability in patients with MS in routine clinical practice in the Czech Republic...
October 26, 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27778334/cognitive-impairment-and-magnetic-resonance-imaging-correlates-in-primary-progressive-multiple-sclerosis
#15
A Gouveia, S P Dias, T Santos, H Rocha, C R Coelho, L Ruano, O Galego, M C Diogo, D Seixas, M J Sá, S Batista
OBJECTIVES: To characterize cognitive impairment in primary progressive multiple sclerosis (PPMS) and to correlate the pattern of cognitive deficits with brain magnetic resonance imaging (MRI) volumetric data. MATERIALS AND METHODS: In a multicenter cross-sectional study, we recruited consecutive patients with PPMS as well as age, sex, and education level-matched healthy controls (HC). All participants underwent neuropsychological (NP) assessment, and brain MRI was performed in patients with PPMS for analysis of lesion load, subcortical GM volumes, and regional cortical volumes...
October 24, 2016: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/27774643/prothrombin-and-factor-x-are-elevated-in-multiple-sclerosis-patients
#16
Kerstin Göbel, Peter Kraft, Susann Pankratz, Catharina C Gross, Catharina Korsukewitz, Robert Kwiecien, Rolf Mesters, Beate E Kehrel, Heinz Wiendl, Christoph Kleinschnitz, Sven G Meuth
Animal models have implicated an integral role for coagulation factors in neuroinflammatory diseases such as multiple sclerosis (MS) beyond their role in hemostasis. However, their relevance in humans requires further elucidation. This study aimed to determine whether levels of coagulation factors differ between patients with neuroimmunological disorders and respective controls. Individuals suffering from relapsing-remitting and secondary progressive MS had significantly higher prothrombin and factor X levels than healthy donors, whereas levels were unchanged in primary progressive MS and neuromyelitis optica patients...
October 24, 2016: Annals of Neurology
https://www.readbyqxmd.com/read/27772763/smoking-increases-the-risk-of-progression-in-multiple-sclerosis-a-cohort-study-in-queensland-australia
#17
Cullen M O'Gorman, Simon A Broadley
BACKGROUND: Cigarette smoking has been associated with increased risk of progressive multiple sclerosis (MS). The effect of smoking status on risk and timing of disease progression in patients with MS in Queensland, Australia has not been established. METHODS: A clinical cohort of 646 cases (531 females, 115 males) were followed from first clinic attendance to onset of clinically determined progressive disease. Progression risk was analysed with gender, age, age of onset, exposure to disease modifying therapy, and smoking status as covariates in a Cox proportional hazards analysis...
November 15, 2016: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/27764667/nr1h3-p-arg415gln-is-not-associated-to-multiple-sclerosis-risk
#18
(no author information available yet)
A recent study by Wang et al. (2016a) claims that the low-frequency variant NR1H3 p.Arg415Gln is sufficient to cause multiple sclerosis in certain individuals and determines a patient's likelihood of primary progressive disease. We sought to replicate this finding in the International MS Genetics Consortium (IMSGC) patient collection, which is 13-fold larger than the collection of Wang et al. (2016a), but we find no evidence that this variant is associated with either MS or disease subtype. Wang et al. (2016a) also report a common variant association in the region, which we show captures the association the IMSGC reported in 2013...
October 19, 2016: Neuron
https://www.readbyqxmd.com/read/27763513/a-personalized-approach-in-progressive-multiple-sclerosis-the-current-status-of-disease-modifying-therapies-dmts-and-future-perspectives
#19
REVIEW
Emanuele D'Amico, Francesco Patti, Aurora Zanghì, Mario Zappia
Using the term of progressive multiple sclerosis (PMS), we considered a combined population of persons with secondary progressive MS (SPMS) and primary progressive MS (PPMS). These forms of MS cannot be challenged with efficacy by the licensed therapy. In the last years, several measures of risk estimation were developed for predicting clinical course in MS, but none is specific for the PMS forms. Personalized medicine is a therapeutic approach, based on identifying what might be the best therapy for an individual patient, taking into account the risk profile...
October 17, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27760868/rituximab-in-multiple-sclerosis-a-retrospective-observational-study-on-safety-and-efficacy
#20
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg, Peter Sundström, Jan Lycke, Fredrik Piehl, Anders Svenningsson
OBJECTIVE: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS). METHODS: In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminology Criteria for Adverse Events were recorded. RESULTS: A total of 822 rituximab-treated patients with MS were identified: 557 relapsing-remitting MS (RRMS), 198 secondary progressive MS (SPMS), and 67 primary progressive MS (PPMS)...
November 15, 2016: Neurology
keyword
keyword
93616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"